| SAM |
drug |
5 |
2 |
S-adenosyl methionine, S-adenosylmethionine |
| samples |
cohort |
13 |
5 |
DNA samples, stock DNAs |
| sarcosine |
drug |
4 |
3 |
N-methylglycine |
| Sardinia |
cohort |
3 |
1 |
Italy: SardiNIA |
| SAS |
cohort |
6 |
2 |
South Asian, South Asian ancestry |
| SASH1 |
gene |
2 |
2 |
SAM and SH3 domain containing 1 |
| SB431542 |
drug |
6 |
5 |
SB, TGFβ inhibitor SB431542 |
| scalp potentials |
phenotype |
2 |
— |
reference-dependent scalp potentials |
| SCD |
gene |
2 |
1 |
stearoyl-CoA desaturase |
| schizoaffective disorder |
phenotype |
16 |
4 |
SCHIZOAF, schizoaffective, schizoaffective concept, schizoaffective disorder |
| schizophrenia |
phenotype |
201 |
136 |
DSM-III-R schizophrenia, F20, MIM 181500, SC, SCH, SCZ, SCZD, SZ, Schizophrenia, adult schizophrenia brains, family history of schizophrenia, genetic or clinical risk for schizophrenia, individuals with schizophrenia, patients with schizophrenia, psychotic disorder, schizophrenia, schizophrenia cohort, schizophrenia diagnosis, schizophrenia patients, schizophrenia subjects, schizophrenia susceptibility, schizophrenia-like illness, schizophrenia-like symptoms, schizophrenic, schizophrenic patients, schizophrenics |
| schizophrenia polygenic risk score |
cohort |
2 |
3 |
PRS, SCZ PRS, genetic risk for schizophrenia, polygenic liability for schizophrenia, polygenic risk for SCZ, polygenic risk for schizophrenia, schizophrenia polygenic risk |
| school performance |
phenotype |
5 |
3 |
poor performance in school, school |
| school problems |
phenotype |
2 |
1 |
school |
| Scn1a |
gene |
3 |
— |
sodium channel, voltage-gated, type I, alpha subunit |
| Scn8a |
gene |
4 |
1 |
Nav1.6, Scn8a |
| screened controls |
cohort |
3 |
1 |
6,068 screened controls with no lifetime subclinical motor or vocal tics, controls |
| SCZ |
phenotype |
12 |
9 |
SCZ, Schizophrenia, schizophrenia |
| SD |
phenotype |
2 |
2 |
self-directedness, substance dependence |
| SDS |
drug |
8 |
1 |
sodium dodecyl sulfate |
